Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Brivio

Showing results (101-110 of 321) with videos related to

Pageof 33
Sort By:
Journal of Biological Regulators and Homeostatic Agents|February 24, 2001
Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic diseaseP Lissoni, F Brivio, F Rovelli, et al.
British Journal of Cancer|November 1, 1991
Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2P Lissoni, F Brivio, S Pittalis, et al.
Anticancer Research|August 17, 2005
A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretionP Lissoni, P Vigano, M Vaghi, et al.
Tumori|December 31, 1992
Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinomaS Barni, P Lissoni, M Cazzaniga, et al.
Cancer|March 15, 1993
In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2P Lissoni, S Pittalis, F Brivio, et al.
Oncology Reports|May 21, 2011
Preoperative neuroimmunotherapy with subcutaneons low-dose interleukin-2 and melatonin in patients with gastrointestinal tumors - its efficacy in preventing surgery-induced lymphocytopeniaF Brivio, P Lissoni, L Fumagalli, et al.
In Vivo (Athens, Greece)|August 22, 2007
Immune and endocrine mechanisms of advanced cancer-related hypercortisolemiaP Lissoni, F Brivio, L Fumagalli, et al.
British Journal of Cancer|January 1, 1994
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanomaP Lissoni, S Barni, G Tancini, et al.
British Journal of Cancer|June 1, 1993
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tractP Lissoni, S Barni, G Tancini, et al.
Anticancer Research|May 16, 2009
Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patientsP Lissoni, F Brivio, L Fumagalli, et al.
Pageof 33

Showing results (101-110 of 321) with videos related to

Sort By:
Pageof 33
Journal of Biological Regulators and Homeostatic Agents|February 24, 2001
Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic diseaseP Lissoni, F Brivio, F Rovelli, et al.
British Journal of Cancer|November 1, 1991
Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2P Lissoni, F Brivio, S Pittalis, et al.
Anticancer Research|August 17, 2005
A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretionP Lissoni, P Vigano, M Vaghi, et al.
Tumori|December 31, 1992
Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinomaS Barni, P Lissoni, M Cazzaniga, et al.
Cancer|March 15, 1993
In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2P Lissoni, S Pittalis, F Brivio, et al.
Oncology Reports|May 21, 2011
Preoperative neuroimmunotherapy with subcutaneons low-dose interleukin-2 and melatonin in patients with gastrointestinal tumors - its efficacy in preventing surgery-induced lymphocytopeniaF Brivio, P Lissoni, L Fumagalli, et al.
In Vivo (Athens, Greece)|August 22, 2007
Immune and endocrine mechanisms of advanced cancer-related hypercortisolemiaP Lissoni, F Brivio, L Fumagalli, et al.
British Journal of Cancer|January 1, 1994
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanomaP Lissoni, S Barni, G Tancini, et al.
British Journal of Cancer|June 1, 1993
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tractP Lissoni, S Barni, G Tancini, et al.
Anticancer Research|May 16, 2009
Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patientsP Lissoni, F Brivio, L Fumagalli, et al.
Pageof 33